APOA5
Reactivity: Human
WB
Host: Rabbit
Polyclonal
unconjugated
Application Notes
Peptide ELISA: 1/64000. Western Blot: 0.3 - 1 μg/mL. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Restrictions
For Research Use only
Concentration
0,5 mg/mL
Buffer
Tris saline, 0.02 % sodium azide, pH 7.3 with 0.5 % bovine serum albumin
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
Apolipoprotein A V is a minor apolipoprotein mainly associated with HDL and to a lesser extent with VLDL. It may also be associated with chylomicrons. It is an important determinant of plasma triglyceride (TG) levels by both being a potent stimulator of apo-CII lipoprotein lipase (LPL) TG hydrolysis and a inhibitor of the hepatic VLDL-TG production rate (without affecting the VLDL-apoB production rate). Apolipoprotein A V activates poorly lecithin:cholesterol acyltransferase (LCAT) and does not enhance efflux of cholesterol from macrophages. Apolipoprotein A V is upregulated by PPARA agonists, which are used clinically to lower serum TG (such as fibrates). It is induced in early phase of liver regeneration. Defects in Apolipoprotein A V gene are a cause of susceptibility to familial hypertriglyceridemia. It is a coronary heart disease risk factor. On a regular diet the patient demonstrates increased plasma VLDL. Plasma triglycerides are persistently increased, while plasma cholesterol and phospholipids are usually within normal limits.Synonyms: APOA5, Apo-AV, ApoA-V, Apolipoprotein A-V, RAP3, Regeneration-associated protein 3